June 27, 2022
In a pair of studies, UC San Diego School scientists have deepened investigations into the genetic origins of nonalcoholic fatty liver disease in children, describing multiple gene variants that contribute to disease risk.
July 12, 2021
UC San Diego researchers discovered that immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis, in mouse models of human disease.
October 15, 2012
The Institute of Medicine (IOM) today announced the names of 70 new members and 10 foreign associates during its 42nd annual meeting. Included are two new members from the University of California, San Diego School of Medicine: David A. Brenner, MD, vice chancellor for Health Sciences and dean of the…
October 28, 2020
U.S. News & World Report named University of California San Diego School of Medicine a top global university and ranked the divisions of Gastroenterology and Hepatology #1 in the world for research.
January 23, 2020
UC San Diego School of Medicine researchers identified several genetic switches, or transcription factors, that determine whether or not liver cells produce collagen — providing a new therapeutic target for liver fibrosis.
December 13, 2016
…enzymes can lead to liver disease and cancer in mice. In human liver tumors, they found that deficiencies in these two enzymes, Shp2 and Pten, are associated with poor prognosis. The study, published December 13 by Cell Reports, provides a new understanding of liver cancer development, new therapeutic approach and…
October 1, 2015
Researchers at the University of California, San Diego School of Medicine say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
November 8, 2017
…drive many cancers, especially liver cancer. Researchers have long thought that’s because inflammation directly affects cancer cells, stimulating their division and protecting them from cell death. But University of California San Diego School of Medicine researchers have now found that chronic liver inflammation also promotes cancer by suppressing immunosurveillance —…
March 8, 2018
…an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings, they say, represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.
June 6, 2018
…from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
